The only growth hormone secretagogue with a history of FDA approval—and what happened after the FDA-approved product disappeared from the market

Sermorelin has something no other growth hormone secretagogue on this site can claim: a history of FDA approval. Geref—the brand name under which sermorelin was sold from 1990 to 2008—went through the full regulatory process, generated clinical trial data in children with growth hormone deficiency, and accumulated post-market safety experience. That history matters. It means sermorelin's basic pharmacology is not speculative.

But it also creates a problem that the sermorelin conversation rarely acknowledges. The compound that was FDA-approved was manufactured to pharmaceutical standards by Serono Laboratories. The sermorelin available today comes from compounding pharmacies operating under 503A or 503B regulations—a fundamentally different quality-control environment. When someone cites "FDA-approved" as a reason to trust sermorelin, they are citing evidence generated by a product that no longer exists.

This gap between the evidence and the current reality is the central editorial tension of sermorelin's story. The mechanism is sound—sermorelin produces the most physiologically accurate growth hormone pulse of any secretagogue in this cluster, with intact somatostatin feedback ensuring the body's natural ceiling remains engaged. The adult clinical data, while modest in scale, consistently shows GH and IGF-1 elevation in elderly populations. The safety profile is the cleanest in the cluster—no cortisol elevation, no appetite stimulation, no prolactin disturbance.

And yet: the evidence base is frozen. No new controlled trial has been conducted since 2008. The adult studies are small (19–30 subjects). The compound is legally accessible—Category 1, legal to compound—but the clinical story stopped two decades ago.

Quick Facts: Sermorelin at a Glance

What Is Sermorelin?

Pronunciation: sir-MORE-eh-lin (also known as GHRH(1-29)NH2, Geref, Sermorelin Acetate)

Your pituitary gland does not decide on its own when to release growth hormone. It takes orders from the hypothalamus—specifically, from a 44-amino acid signaling peptide called growth hormone-releasing hormone (GHRH). Sermorelin is the first 29 amino acids of that signaling peptide. And those 29 amino acids are all you need. The entire biological activity of GHRH—its ability to bind the GHRH receptor, trigger the intracellular signaling cascade, and produce a growth hormone pulse—resides in this N-terminal fragment. The remaining 15 amino acids of full-length GHRH contribute to stability but add nothing to receptor activation.

This is not a drug designed to do something new. It is a synthetic copy of a signal your body already sends. The difference between injecting sermorelin and waiting for your hypothalamus to release GHRH is timing and dosage, not mechanism. The GH pulse that follows a sermorelin injection is pharmacologically indistinguishable from a natural GHRH-triggered pulse—complete with the somatostatin feedback that prevents GH from rising beyond what the pituitary's own negative feedback loop allows.

That self-limiting property is sermorelin's defining pharmacological feature and the reason it was FDA-approved while more potent GH secretagogues were not. You cannot overdose the GH response with sermorelin the way you can with exogenous GH or with ghrelin receptor agonists that bypass somatostatin control.

Origins and Discovery

The isolation and characterization of GHRH in the early 1980s was a landmark in endocrinology. Two groups—Guillemin's at the Salk Institute and Vale's—independently identified the 44-amino acid peptide, both working from ectopic GHRH-secreting pancreatic tumors (a remarkable clinical shortcut: tumors that produce GHRH in large quantities made it possible to purify enough peptide for characterization).

Structure-activity studies quickly established that the N-terminal 29 amino acids contained full biological activity. Serono Laboratories developed the synthetic GHRH(1-29)NH₂ as sermorelin acetate, conducting clinical trials in pediatric growth hormone deficiency that led to FDA approval of Geref in 1990. A second formulation (0.5 mg and 1.0 mg vials) was approved in 1997.

Geref served two clinical purposes: as a diagnostic tool (a single IV dose could distinguish pituitary from hypothalamic GH deficiency) and as a therapeutic agent (daily subcutaneous injections in GH-deficient children). The Geref International Study Group's multicenter trial demonstrated that sermorelin increased height velocity from 4.1 to 8.0 cm/year in prepubertal GH-deficient children—less potent than recombinant GH (somatropin) but with a fundamentally different risk profile.

EMD Serono (Serono's successor) discontinued Geref in 2008. The FDA's 2013 Federal Register notice confirmed the withdrawal was for commercial reasons—supply chain issues and competition from long-acting somatropin—not safety or effectiveness concerns. This distinction matters: sermorelin was not pulled because something went wrong. It was pulled because something cheaper and more convenient took its place.

Mechanism of Action

Sermorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. GHRHR is a G-protein-coupled receptor that signals through the Gs → adenylyl cyclase → cAMP → protein kinase A (PKA) cascade. PKA activation opens voltage-gated calcium channels and mobilizes intracellular calcium stores, triggering exocytosis of preformed GH-containing secretory granules.

The critical distinction from ghrelin receptor (GHS-R1a) agonists: GHRHR signaling is fully subject to somatostatin negative feedback. Somatostatin, released by hypothalamic neurons in response to rising GH levels, acts on somatostatin receptors (SSTR2 and SSTR5) on somatotrophs to inhibit cAMP production—directly opposing the GHRHR signal. This creates a self-limiting ceiling: sermorelin can trigger GH release, but the amplitude of the pulse is constrained by the same feedback loop that governs endogenous GHRH-driven secretion.

GHS-R1a agonists (MK-677, ipamorelin, GHRPs) partially bypass this ceiling because the Gq/11 signaling pathway they activate converges with but is not identical to the Gs/cAMP pathway—meaning somatostatin's inhibitory effect is less complete.

Synergy with GHS-R1a agonists: GHRHR and GHS-R1a pathways are complementary. Combining sermorelin (GHRHR) with ipamorelin or a GHRP (GHS-R1a) produces synergistic GH release exceeding what either achieves alone—because they activate two distinct signaling cascades on the same cell type. This is the pharmacological rationale for the CJC-1295/ipamorelin combination stack popular in clinical anti-aging protocols.

What sermorelin does NOT stimulate: Unlike GHRP-6 and hexarelin (which activate cortisol and prolactin release through GHS-R1a's broader signaling), sermorelin at GHRH-receptor-stimulating doses produces no cortisol elevation, no ACTH stimulation, no prolactin disturbance, and no appetite stimulation. The GHRHR pathway is specific to growth hormone release.

Key Research Areas and Studies

Pediatric Growth Hormone Deficiency — The FDA Approval Basis

The Geref International Study Group (PMID 8772599, 1996) conducted the multicenter trial that anchored FDA approval. In 110 prepubertal children with growth hormone deficiency (86 evaluable), daily subcutaneous sermorelin increased height velocity from 4.1 cm/year to 8.0 cm/year at 6 months, sustained at 12 months. Approximately 74% of patients achieved a "good response."

Sermorelin was explicitly positioned as less potent than recombinant GH (somatropin) but with advantages: it stimulates endogenous GH release rather than replacing it, preserves the pulsatile pattern, maintains feedback regulation, and carries lower risk of adverse metabolic effects. The trade-off was always efficacy versus physiological fidelity.

Adult Somatopause and Anti-Aging

Khorram et al. 1997 (PMID 9141536) is the most comprehensive adult study. In a single-blind, placebo-controlled RCT of 19 men and women aged 55–71, 16 weeks of sermorelin increased nocturnal GH secretion, elevated IGF-1, and produced sex-specific effects: men gained 1.26 kg lean mass, improved insulin sensitivity, and reported improved libido. Women showed less benefit—a sex difference consistent with the known sexual dimorphism of GH secretion patterns. A transient lipid elevation was noted.

Corpas et al. 1992 (PMID 1379256) demonstrated that 14 days of twice-daily sermorelin in elderly men restored 24-hour GH and IGF-1 to near-young levels. The high dose (1 mg BID) produced IGF-1 elevation that persisted for 2 weeks after cessation—suggesting a priming effect on the GH axis rather than simple pharmacodynamic duration.

Vittone et al. 1997 (PMID 9005976) confirmed that 6 months of subcutaneous sermorelin was superior to intranasal administration for IGF-1 normalization and lean mass improvement—establishing the SC route as standard of care.

The Sleep–GH Bidirectional Relationship

Sermorelin's pre-bedtime dosing protocol is not arbitrary. GHRH promotes slow-wave sleep (SWS), and SWS is the sleep stage during which the largest endogenous GH pulses occur. This creates a positive feedback loop: sermorelin injection before sleep amplifies the natural nocturnal GH pulse AND may improve the sleep architecture that generates it. The Khorram study documented improved sleep quality as a secondary outcome. While sermorelin-specific sleep polysomnography data is limited, the GHRH–SWS relationship is well-established in the broader endocrinology literature.

Pharmacokinetics

Wilton et al. 1993 (PMID 8329825) established sermorelin's PK profile: IV lowest effective dose 0.25 µg/kg, optimal 1–2 µg/kg. Subcutaneous bioavailability approximately 70%. Intranasal bioavailability only 3–5%—clinically impractical and abandoned as a route. Half-life approximately 10–20 minutes via SC administration.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Geref International Study Group 1996 — The FDA Approval Trial

Design: Multicenter, open-label. N: 110 (86 evaluable) prepubertal children with GH deficiency. Duration: 6–12 months. Key findings: Height velocity doubled (4.1→8.0 cm/yr). ~74% good response. Sustained at 12 months. Limitations: Open-label (no placebo arm). Pediatric population—not directly applicable to adult anti-aging use. Pharmaceutical-grade Geref—not compounded product. PMID: 8772599

Khorram et al. 1997 — The Anti-Aging Study

Design: Single-blind, RCT, placebo-controlled. N: 19 men and women (55–71 years). Duration: 16 weeks. Key findings: Nocturnal GH secretion increased. IGF-1 elevated. Men: +1.26 kg lean mass, improved insulin sensitivity, improved libido. Women: less benefit. Transient lipid elevation. Limitations: Small sample. Single-blind (not double-blind). Sex differences not fully explored. 16 weeks only. PMID: 9141536

Corpas et al. 1992 — The GH Restoration Study

Design: Controlled, dose-escalation. N: 19 (9 young, 10 elderly) healthy men. Duration: 14 days. Key findings: High dose (1 mg BID) restored elderly 24-hr GH and IGF-1 to near-young levels. Improved waist-to-hip ratio. IGF-1 elevation persisted 2 weeks post-cessation. Limitations: 14 days only. All male. Small sample. No functional outcomes measured. PMID: 1379256

Vittone et al. 1997 — SC vs. Intranasal Comparison

Design: Controlled comparison. N: ~20 (estimated). Duration: 6 months. Key findings: Subcutaneous route superior to intranasal for IGF-1 normalization and lean mass improvement. Established SC as standard route. Limitations: Small sample. Not placebo-controlled against no treatment. Primarily a route comparison, not efficacy trial. PMID: 9005976

Wilton et al. 1993 — The Pharmacokinetic Study

Design: Pharmacokinetic. N: 30 healthy men (19–43 years). Key findings: IV lowest effective dose 0.25 µg/kg; optimal 1–2 µg/kg. SC bioavailability ~70%. Intranasal only 3–5%. Half-life ~10–20 min. Limitations: PK study, not efficacy. Young healthy volunteers only. PMID: 8329825

What the Landscape Reveals

Sermorelin's human evidence has a paradoxical structure. It is the most clinically validated compound in the cluster—by virtue of FDA approval—but the validation is narrower than it appears. The FDA approval was for pediatric GH deficiency, not adult anti-aging. The adult studies are consistently small (n=19–30) and short (2 weeks to 6 months). No Phase III adult trial was ever completed. The evidence base is frozen since 2008. And the product that generated all this evidence—pharmaceutical-grade Geref—no longer exists.

Safety, Risks, and Limitations

Injection Site Reactions

The most common adverse effect in clinical trials. Pain, redness, and swelling at the injection site were reported by a significant minority of patients. Generally mild and self-limiting.

Antibody Formation

Some patients in clinical studies developed anti-sermorelin antibodies. In most cases, these did not neutralize the GH-stimulating effect. However, antibody formation is a known risk with any exogenous peptide, and it may contribute to tachyphylaxis (reduced response over time) in a subset of users.

Hypothyroidism Signal

A 6.5% incidence of hypothyroidism was reported in clinical studies—higher than background rates. The mechanism is not fully characterized. GH elevation can increase peripheral conversion of T4 to T3, potentially depleting T4. Users on long-term sermorelin protocols should monitor thyroid function.

Compounding Quality Risk

This is the elephant in the room. All published safety data was generated with pharmaceutical-grade Geref manufactured under cGMP conditions. Current compounded sermorelin products are manufactured under 503A or 503B regulations, which impose less stringent quality requirements. Potency variation, sterility failures, and purity issues have been documented across the compounding pharmacy landscape (not specific to sermorelin, but applicable). The safety profile of pharmaceutical-grade sermorelin does not automatically transfer to compounded products.

What Is NOT Known (Adult Use)

• Long-term safety beyond 6 months in adults (no long-term adult trial exists)
• Cardiovascular effects of sustained GH elevation in aging populations
• Cancer risk from chronic IGF-1 elevation (theoretical concern, no sermorelin-specific data)
• Interaction with exogenous testosterone, thyroid supplementation, or other commonly co-administered hormones in anti-aging protocols

Legal and Regulatory Status

Sermorelin occupies the most favorable regulatory position of any GH secretagogue in Cluster D:

• FDA status: Category 1 on the FDA bulk drug substance evaluation list. This means sermorelin is eligible for compounding by both 503A (traditional compounding pharmacies) and 503B (outsourcing facilities). This is a critical practical advantage—while ipamorelin and CJC-1295 were removed from Category 2 in September 2024 (creating regulatory uncertainty), sermorelin's compounding status has remained stable.
• Historical approval: Geref was FDA-approved from 1990/1997 to 2008. The FDA's 2013 Federal Register determination confirmed the withdrawal was commercial, not safety/efficacy-related.
• DEA scheduling: Not a controlled substance.
• WADA status: Prohibited under S2 (Peptide Hormones, Growth Factors, Related Substances). Banned both in-competition and out-of-competition. LC-MS/MS detection methods for GHRH analogs including sermorelin have been developed (Cristea et al. 2023, PMID 37806509).
• Prescribing: Available by prescription through compounding pharmacies. Requires a prescriber-patient relationship. This is the legitimate access pathway—unlike research chemical purchases for most other GH secretagogues.

Research Protocols and Formulation Considerations

Sermorelin is available as: - Lyophilized powder for reconstitution: Standard compounding pharmacy format. Reconstituted with bacteriostatic water. Requires refrigeration after reconstitution. - Pre-filled syringes: Some 503B facilities offer pre-filled formats.

Storage: Unreconstituted vials are stable at room temperature or refrigerated. Reconstituted sermorelin should be refrigerated (2–8°C / 36–46°F) and used within 14–30 days depending on formulation.

Typical presentation: 2 mg, 3 mg, 6 mg, or 9 mg multi-dose vials. Reconstitution volume varies by concentration target.

Dosing in Published Research

⚠️ Citation Correction: The existing article cites "Walker RF, et al. J Gerontol 1994" with dose "0.5–2 mg/day SC" for "healthy older men (mean age 69)." This citation is incorrect. The actual Walker RF sermorelin publication is a 2006 editorial (PMID 18046908) in Clinical Interventions in Aging. The dosing data attributed to "Walker 1994" likely comes from Corpas 1992 or Khorram 1997. This must be corrected in the final article.

Dosing in Self-Experimentation Communities

Community dosing protocols for sermorelin are more standardized than most compounds in this cluster, partly because of its history as a prescribed medication:

• Standard community dose: 200–300 µg (0.2–0.3 mg) subcutaneous injection, once daily before bedtime
• Clinical anti-aging protocols: Many prescribing physicians use 200–500 µg SC nightly, often based on the Corpas and Khorram studies
• Combination stacks: Frequently paired with ipamorelin (GHS-R1a agonist) for synergistic GH release via complementary receptor pathways. This combination (sometimes called "serm/ipa") is one of the most widely prescribed anti-aging peptide protocols.
• Cycle length: Many clinical protocols run 3–6 months continuously. Some include 1-month breaks between cycles; others maintain continuous use.
• Timing: Universally dosed before bedtime to amplify the natural nocturnal GH pulse. This is consistent with the clinical trial protocols (Corpas, Khorram, Vittone all used bedtime dosing).

No large-scale controlled trial has validated community dosing protocols for healthy adults seeking anti-aging or performance benefits. The published adult studies (Khorram, Corpas) used similar dose ranges but in small populations over limited durations.

Combination Stacks

Research into Sermorelin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Sermorelin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Sermorelin occupies a unique position in the growth hormone secretagogue landscape. It is the only compound in Cluster D with a genuine history of FDA approval—a distinction that gives it clinical credibility no other GH secretagogue can claim. The mechanism is the most physiologically conservative in the cluster: a short-acting GHRH analog that triggers a natural GH pulse with intact somatostatin feedback. No cortisol. No appetite stimulation. No prolactin disturbance. The cleanest endocrine profile available.

The evidence supports these claims: clinical trials in pediatric GH deficiency established efficacy for the FDA-approved indication, and adult studies in elderly populations consistently show GH/IGF-1 restoration, modest lean mass gains, and improved sleep quality. The safety profile, accumulated over nearly two decades of clinical use, is the most reassuring in the cluster.

But the story has a gap at its center. The product that generated all this evidence—pharmaceutical-grade Geref—no longer exists. The adult studies are small (19–30 subjects) and short (2 weeks to 6 months). No Phase III adult trial was ever completed. The evidence base has been frozen since 2008. And the population currently using sermorelin (healthy adults seeking anti-aging benefits through compounding pharmacies) is not the population in which it was studied or approved.

Verdict Recapitulation

Sermorelin earns a Reasonable Bet verdict because the mechanism is validated by FDA review and the evidence is genuine but modest in scale. The gap between the clinical data (pharmaceutical-grade Geref in GH-deficient populations) and the current reality (compounded sermorelin in healthy adults) is real and irreducible. Sermorelin is the "known quantity" in a cluster full of more exciting but less proven compounds. For users who prioritize safety, physiological fidelity, and regulatory legitimacy over maximal GH output, it remains the most defensible choice. For users who want the strongest possible data, the honest answer is that even the "most validated" compound in this cluster has an evidence base that is smaller, older, and narrower than it appears.

For readers considering Sermorelin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Sermorelin

Further Reading and Resources

If you want to go deeper on Sermorelin, the evidence landscape for growth hormone secretagogues peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Growth Hormone Secretagogues Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Sermorelin — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Geref International Study Group. Effect of biosynthetic human growth hormone-releasing factor (sermorelin) in growth hormone-deficient children. Acta Paediatr Suppl. 1996;417:90–92. PMID 8772599
2. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH₂ in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472–1479. PMID 9141536
3. Corpas E, Harman SM, Piñeyro MA, et al. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-29 for 14 days increase GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(1):101–105. PMID 1379256
4. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89–96. PMID 9005976
5. Wilton P, Sietnieks A, Gunnarsson R, et al. Pharmacokinetic profile of recombinant human growth hormone-releasing factor in healthy male volunteers. Eur J Clin Pharmacol. 1993;44(2):107–111. PMID 8329825
6. Thorner MO, Chapman IM, Gaylinn BD, et al. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Prog Horm Res. 1997;52:215–244. PMID 9238854
7. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308. PMID 18046908
8. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139–157. PMID 18031173
9. Chang CN, et al. High-throughput drug screening identifies sermorelin as a potential drug for recurrent glioma. Int J Mol Sci. 2021;22(7):3602. PMID 33842627
10. Cristea C, et al. LC-MS/MS method for GHRHs including sermorelin in urine for anti-doping application. Drug Test Anal. 2023;15(11-12):1381–1393. PMID 37806509

---